Key facts
- It has raised $1.6M; the latest was Angel (individual) ($110K) in Sep 2025.
- Notable investors include US National Science Foundation, MassChallenge, National Aeronautics and Space Administration.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Xheme
- ·The full record, as it builds
Funding rounds
No funding rounds for Xheme are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Xheme
Developer of a cell-health engineering platform designed to reduce oxidative stress and enhance cell viability. The company offers technologies that improve stability in bioprocessing and cell therapeutics, enabling biomanufacturers and vital-fluid handlers, enhanced yields and extended quality retention.
- Sector
- Business Products and Services (B2B)
- HQ
- Newton, MA, United States
- Founded
- 2019
- Employees
- 6
- Website
- xhemeinc.com/
- Ownership
- Privately Held (backing)
Xheme doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Xheme shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Xheme in its N-PORT filings yet. We sweep new filings monthly.